Overview

Decitabine and Anti-PD-1 in R/R DLBCL

Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
Patients with relapsed/refractory diffuse large B cell lymphoma with extranodal (esp. central nervous system) involvement treated with Low-Dose Decitabine plus anti-PD-1 regimen. 3 weeks for a cycle, with a total of 2 years or until the disease progress esor unacceptable toxicity occurs, or the patient decides to withdraw from the trial.
Phase:
Phase 2
Details
Lead Sponsor:
Chinese PLA General Hospital
Treatments:
Decitabine